Sign in
Taking people in United StatesNo phase

Testing a Dietary Supplement for Hormone Balance in Women With PCOS Symptoms

Tests a dietary supplement against placebo in women reporting polycystic ovary syndrome symptoms.

Key facts

Who runs it
Mila Mend Inc.
Where
Los Angeles, United StatesSee the site
Trial code
Registry title
This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.
Status
Recruiting
People taking part
225 people, planned
Started
23 Dec 2025
Expected to end
30 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • A dietary supplement powder for women
  • Placebo
Record updated
13 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18-40 who have PCOS or likely PCOS symptoms, to test a hormone balance supplement against a placebo.

Age
18 to 40 years, inclusive.
Sex
Women only.
Disease stage
A known diagnosis of PCOS, or likely PCOS: fewer than 9 menstrual cycles in the past year plus signs of high male hormones (hirsutism, acne, female-pattern hair loss). BMI 18.5-35. Average cycle length of the last 3 cycles must not be over 50 days.
Earlier treatment
No hormonal contraceptives, Co-Q10, high-dose vitamin B or inositol supplements in the last 6 months. No pioglitazone, spironolactone or metformin in the last 6 months. No investigational treatment in the last 30 days.

Main reasons for not taking part

  • Perimenopausal or menopausal
  • Currently pregnant, planning pregnancy in the next 3 months, or breastfeeding
  • Diabetes managed with insulin, TZDs or metformin
  • Other causes of irregular periods, such as thyroid disease or Cushing syndrome
  • Chronic liver, kidney or heart disease, or a disorder that affects nutrient absorption

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Females between 18-40 years old, inclusive
  • Known diagnosis of Polycystic Ovarian Syndrome (PCOS) OR likely have PCOS as defined by presence of:
  • Oligomenorrhea (<9 menstrual cycles in the past year)
  • Signs of hyperandrogenism (hirsutism, acne, female-pattern hair loss)
  • Has recorded menstrual cycle duration of at least 3 menstrual cycles in the past year
  • BMI of 18.5-35
  • Owns or is willing to purchase a personal digital weight scale for monthly weight measurement
  • In good general health at the time of screening (Investigator discretion)
  • Able to read and understand English
  • Able to read, understand, and provide informed consent
  • Able to use a personal smartphone device and download Chloe by People Science
  • Able to receive shipment of the product at an address within the United States
  • Able to complete study assessments over the course of up to 16 weeks

Who cannot take part

  • Concomitant Therapies:; Use of hormonal contraceptives within the last 6 months; Use of a Co-Q10 supplement within the last 6 months; Use of any high dose vitamin B supplements in the last 6 months; Received any investigational therapies or treatments within 30 days prior to randomization; Use of any other alpha-inositol/myo-inositol supplement in the last 6 months; Pioglitazone, spironolactone or metformin in the previous 6 months
  • Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses are excluded:
  • Participants diagnosed with Diabetes Mellitus (DM) for both Type I and Type II, who are managed with Insulin, Thiazolidinediones (TZDs) or Metformin
  • Known diagnosis of other causes of oligomenorrhea (e.g. thyroid disease, primary ovarian insufficiency, hyperprolactinemia, Cushing syndrome, any disorders of sexual development or Obesity)
  • Chronic hepatic, renal, or cardiovascular disease (excluding hypertension)
  • Known disorders that would affect nutrient absorption (e.g., Crohn's Disease, ulcerative colitis, chronic diarrhea, Celiac Disease, Irritable Bowel Syndrome, eating disorder)
  • Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder
  • Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes
  • Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes
  • Other possible causes of oligomenorrhea such as history of disordered eating, chronic jetlag or shiftwork
  • Known hypersensitivity or previous allergic reaction to the product ingredients: Vitamin B6 (as Pyridoxal-5-Phosphate), Folate (as L-5-Methyltetrahydrofolate Calcium), Zinc (as Zinc Picolinate), Selenium (as L-Selenomethionine), Chromium (as Chromium Picolinate), Myo-inositol, D-chiro-inositol, Co-enzyme Q10, Alpha Lipoic Acid, L-Glutamine, L-Carnitine Tartrate, L-Lysine (as L-Lysine HCl), L-Threonine, L-Tryptophan, beet root powder, hibiscus, or spirulina (algae) or citric acid
  • Any potential participants who:
  • Do not have a personal smartphone, internet access, or unwilling to download Chloe
  • Rates the impact of PCOS on their overall quality of life as "Rarely/Seldom" or "Not at all"
  • Average cycle length of last 3 cycles is >50 days
  • Perimenopausal or menopausal
  • Currently pregnant, planning to become pregnant in the next 3 months, or breastfeeding
  • Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

Where in United States

  • People Science, Inc.Los Angeles, United StatesContact: Noah Craft, M.D., Ph.D.Taking people

About the trial

What the trial wants to find out

The rationale for this study is to observe the impact of a consumer-grade commercially available product called Milamend Hormone Balance on quality of life and hormonal health in women with self-reported symptoms associated with Polycystic Ovarian Syndrome (PCOS). Additionally, the study aims to observe the impact of the product on menstrual cycle structure and associated symptoms, on reproductive and metabolic markers, on body image concerns, anxiety and general well-being. A consumer-driven, decentralized observational clinical research study is therefore well-suited for examining the effects of this product in this population.

Read full original descriptionShow less

We will examine the outcomes in a broad age-range of premenopausal women who have chosen to try this product. The study will incorporate participant reported outcome questionnaires and surveys and at-home blood specimen collection. There is no "doctor-patient" relationship as part of this research since the participant as a consumer is making the informed choice to try the product and take part in the observational process with self-reported measures, cycle tracking and at-home blood sample collection. Findings from this study will contribute knowledge toward the tolerability and formulation of the product and the design of future studies.

The 2 groups in the trial

  • Placebo ArmPlacebo, for comparison

    Control Arm using the placebo

    Treatment: Placebo

  • Study Product ArmTreatment being tested

    Experimental study arm will use the Milamend Hormone Balance supplement

    Treatment: A dietary supplement powder for women

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Impact of Milamend on Quality of Life and Hormonal Health in Women With Self-Reported Symptoms Associated With Polycystic Ovary Syndrome (PCOS)
Plain-language title
Testing a Dietary Supplement for Hormone Balance in Women With PCOS SymptomsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07764328, who can take part
Record updated
13 August 2026